Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: A semiquantitative study of immunoreactivities using tissue array

Gynecologic Oncology

Volumn 108, Issue 3, 2008, Pages 533-542

  Wang, Po Hui ^a,b   Ko, Jiunn Liang ^b   Tsai, Hsiu Ting ^b   Yang, Shun Fa ^b   Han, Chih Ping ^a,b   Lin, Long Yau ^a,b   Chen, Gin Den ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cervical cancer; Lymph node metastasis; Matrix metalloproteinase 2; Parametrium invasion; Tissue array

Indexed keywords

GELATINASE A;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY; TUMOR CELL; UTERINE CERVIX CANCER;

EID: 39249084423     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.11.018     Document Type: Article

References (41)

1. Matrisian L. The matrix-degrading metalloproteinases. Bioessays 14 (1992) 455-463
2. Nelson A.R., Fingleton B., Rothenbers M.L., and Matrsian L. Matrix metalloproteinases: biologic and clinical implications. J Clin Oncol 18 (2000) 1135-1149
3. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev 2 (2002) 163-176
4. Tokuraku M., Sato H., Murakami S., Okada Y., Watanabe Y., and Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT1-MMP) and with lymph node metastasis. Int J Cancer 64 (1995) 355-359
5. Remacle A.G., Noel A., Duggan C., McDermott E., O'Higgins N., Foidart J.M., et al. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77 (1998) 926-931
6. Campo E., Tavassoli F.A., Charonis A.S., Stetler-Stevenson W.G., Liotta L.A., and Merino M.J. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumours of the ovary. Am J Pathol 6 (1992) 500-507
7. Liotta L.A., Rao C.N., and Barsky S.H. Tumor invasion and the extracellular matrix. Lab Invest 49 (1983) 636-649
8. Garzetti G.G., Ciavattini A., Lucarini G., Goteri G., Nictolis M.D., and Biagini G. Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol Oncol 61 (1996) 197-203
9. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., and Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284 (1980) 67-68
10. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., and Quaranta V. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 277 (1997) 225-228
11. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 (2002) 350-392
12. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
13. Al Haddad S., Zhang Z., Leygue E., Snell L., Huang A., Niu Y., et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 155 (1999) 2057-2066
14. Handra-Luca A., Bilal H., Bertrand J.C., and Fouret P. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 163 (2003) 957-967
15. Chang H., Su J.M., Huang C.C., Liu L.C., Tsai C.H., Chou M.C., et al. Using a combination of cytochrome P450 1B1 and b-catenin for early diagnosis and prevention of colorectal cancer. Cancer Detec. Prev. 29 (2005) 562-569
16. Sheu B.C., Lien H.C., Ho H.N., Lin H.H., Chow S.N., Huang S.C., et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 63 (2003) 6537-6542
17. Davidson B., Goldberg I., Kopolovic J., Lerner-Geva L., Gotlieb W.H., Ben-Baruch G., et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 73 (1999) 372-382
18. Hoyhtya M., Fridman R., Komarek D., Porter-Jordan K., Stetler-Stevenson W.G., Liotta L.A., et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 56 (1994) 500-505
19. Levy A.T., Cioce V., Sobel M.E., Garbisa S., Grigioni W.F., Liotta L.A., et al. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51 (1991) 439-444
20. Monteagudo C., Merino M.J., San J.J., Liotta L.A., and Stetler-Stevenson W.G. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 136 (1990) 585-592
21. Garzetti G.G., Ciavattini A., Lucarini G., Goteri G., Romanini C., and Biagini G. The 72-kDa metalloproteinase immunostaining in cervical carcinoma: relationship with lymph nodal involvement. Gynecol Oncol 60 (1996) 271-276
22. Yoshida H., Sumi T., Hyun Y., Nakagawa E., Hattori K., Yasui T., et al. Expression of surviving and matrix metalloproteinases in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Oncol Rep 10 (2003) 45-49
23. Rauvala M., Aglund K., Puistola U., Turpeenniemi-Hujanen T., Horvath G., Willén R., et al. Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression. Int J Gynecol Cancer 16 (2006) 1297-1302
24. John A., and Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7 (2001) 14-23
25. Brinckerhoff C.E., and Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3 (2002) 207-214
26. Hrabec E., Naduk J., Strek M., and Hrabec Z. Type IV collagenases (MMP-2 and MMP-9) and their substrates-intracellular proteins, hormones, cytokines, chemokines and their receptors. Postepy Biochem 53 (2007) 37-45
27. Giancotti F.G., and Ruoslahti E. Integrin signaling. Science 285 (1999) 1028-1032
28. McCawley L.J., and Matrisian L.M. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6 (2000) 149-156
29. Montgomery A.M., Reisfeld R.A., and Cheresh D.A. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci U S A 91 (1994) 8856-8860
30. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., and Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277 (1997) 225-228
31. Jin J.S., Hsieh D.S., Lin Y.F., Wang J.Y., Sheu L.F., and Lee W.H. Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 13 (2006) 573-580
32. Lam J.S., Belldegrun A.S., and Figlin R.A. Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy. Clin Cancer Res 10 (2004) 6304-6309
33. Nagase H., and Woessner J. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
34. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
35. Ra H.J., and Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol 26 (2007) 587-596
36. Gupta S.P. Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors. Chem Rev 107 (2007) 3042-3087
37. Stolow M.A., Bauzon D.D., Li J., Sedgwick T., Liang V.C., Sang Q.A., et al. Identification and characterization of a novel collagenase in Xenopus laevis: possible roles during frog development. Mol Biol Cell 7 (1996) 1471-1483
38. Yang M., and Kurkinen M. Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts. CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain. J Biol Chem 273 (1998) 17893-17900
39. Martin M.D., and Matrisian L.M. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26 (2007) 717-724
40. Zucker S., Cao J., and Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19 (2000) 6642-6650
41. Tee Y.T., Han C.P., Ko J.L., Chen G.D., Yang S.F., Chen S.C., et al. Evaluation of matrix metalloproteinase-2 expression in cervical carcinogenesis using tissue array and integrated optical density for immunoreactivity. Reprod Sci 14 (2007) 719-726